Drug		N of Cases
Antibiotics		13
	Antituberculars	4
	Amoxicillin-Clavulanate	3
	Nitrofurantoin	1
	Piperacillin/Tazobactam	1
	Trimethoprim/Sulfamethoxazole	1
	Fluconazole	1
	Oxacillin	1
	Meropenem	1
Herbs and Dietary Supplements		10
	Camellia sinensis	3
	Peumus boldus	2
	Moringa oleifera	1
	Plantago major L.	1
	Ruellia bahiensis	1
	Senna alexandrina	1
	Rip Kutz	1
Anabolic Steroids		4
	Stanozolol	4
NSAIDs		5
	Nimesulide	4
	Diclofenac	1
Neuroleptics		5
	Phenytoin	2
	Chlorpromazine	2
	Phenobarbital	1
Antiretrovirals		3
	Dolutegravir	2
	Efavirenz	1
Others		7
	Acetaminophen	1
	Propylthiouracil	1
	Asparaginase	1
	Fluconazole	1
	Infliximab	1
	Oxaliplatin	1
	Etrolizumab	1

https://doi.org/10.1016/j.aohep.2021.100416

P-53 FAILURE IN ALL STEPS OF HEPATOCELLULAR CARCINOMA SURVEILLANCE PROCESS IS FREQUENT IN DAILY PRACTICE.

Melisa Dirchwolf[1], Sebastián Marciano[2], Andres E. Ruf[1], Amit G. Singal[3], Vanina D'Ercole[4], Paola Coisson[5], Alina Zerega[6,7], Federico Orozco[8], Ana Palazzo[9], Eduardo Fassio[10], Diego Arufe[11], Margarita Anders[12], Claudia D'Amico[13], Luis Gaite[14,15], Marcos Thompson[16], Daniela Perez[9], Leila Haddad[2], Ezequiel Demirdjian[11], Moira Zunino[9], Adrián Gadano[2], María Dolores Murga[9], Carla Bermudez[2], Jesica Tomatis[1], Nadia Grigera[12], Florencia Antinucci[12], Manuel Baravalle[1], Maria Mercedes Rodriguez Gazari[17], Melina Ferreiro[18], Manuel Barbero[5], Andrea Curia[18], Manuel Demonte[14], Gisela Gualano[10]

[1] *Hospital Privado de Rosario, Rosario, Santa Fe, Argentina*
[2] *Hospital Italiano de Buenos Aires, Caba, Argentina*
[3] *Department Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA*
[4] *Hospital Complejo Médico de la Policía Federal Churruca – Visca, Caba, Argentina*
[5] *Hospital el Cruce – Néstor Kirchner, Florencio Varela, Buenos Aires, Argentina*
[6] *Sanatorio Allende, Córdoba, Argentina*
[7] *Hospital Córdoba, Córdoba, Córdoba, Argentina*
[8] *Hospital César Milstein, Caba, Argentina*
[9] *Hospital Ángel C. Padilla, San Miguel de Tucumán, Tucumán, Argentina*
[10] *Hospital Nacional Prof. Alejandro Posadas, El Palomar, Buenos Aires, Argentina*
[11] *Sanatorio Sagrado Corazón, Caba, Argentina*
[12] *Hospital Alemán, Caba, Argentina.*
[13] *Centro Especialidades Médicas Ambulatoria, Mar del Plata, Buenos Aires, Argentina*
[14] *Hospital José M. Cullen, Santa Fe, Argentina*
[15] *Clínica de Nefrología, Urología y Enfermedades Cardiovasculares, Santa Fe, Argentina*
[16] *Hospital Universitario Austral, Pilar, Buenos Aires, Argentina*
[17] *Hospital Británico, Caba, Argentina*
[18] *Hospital de Clínicas José de San Martín (UBA), Caba, Argentina*

Introduction: Failures at any step in the hepatocellular carcinoma (HCC) surveillance process can result in HCC diagnostic delays and associated worse prognosis.

Objectives: We aimed to estimate the prevalence of surveillance failure and its associated risk factors in patients with HCC in Argentina, considering three steps: 1) recognition of at-risk patients, 2) implementation of HCC surveillance, 3) success of HCC surveillance.

Methods: We performed a multi-center cross-sectional study of patients at-risk for HCC in Argentina seen between10.01.2018 and 10.30.2019. Multivariable logistic regression analysis was used to identify correlates of surveillance failure.

Results: Of 301 included patients, the majority were male (74.8%) with a mean age of 64 years old. At the time of HCC diagnosis, 75 (24.9%) patients were unaware of their diagnosis of chronic liver disease, and only 130 (43.2%) patients were under HCC surveillance. Receipt of HCC surveillance was significantly associated with follow-up by a hepatologist. Of 119 patients with complete surveillance, surveillance failure occurred in 30 (25.2%) patients. Patients under complete surveillance were significantly more likely to be diagnosed within Milan criteria than those without surveillance (75% vs. 50%, $p<0.001$),(Figure). Surveillance failure was significantly associated with alpha fetoprotein ≥20 ng/ml (OR 4.0, CI 95% 1.43-11.55).

Conclusions: HCC surveillance failure was frequent in all the evaluated steps. These data should help guide strategies to improve the implementation and results of HCC surveillance in our country.

Figure. Milan criteria at diagnosis according to HCC surveillance.



https://doi.org/10.1016/j.aohep.2021.100417

P-54 STUDY OF BACTERIAL INFECTIONS IN 134 HOSPITALIZATIONS OF PATIENTS WITH LIVER CIRRHOSIS

Rodrigo Fedatto Beraldo[1],
Maria Clara Vidal Regueiro[2], Thaís Gagno Grillo[1],
Maria Natália Marques dos Santos[1,2],
Mariana Barros Marcondes[1],
Luciana Almeida Rocha[1], Giovanni Faria Silva[1]

[1] *State University São Paulo, Botucatu, Brasil*
[2] *Taubaté University, Taubaté, Brasil, Paraná Federal University, Curitiba, Brasil*

Background: In cirrhotic, bacterial infections are frequent and demands 25-40% of hospitalizations, can trigger decompensations, organ failure, even death. Spontaneous bacterial peritonitis (SBP), urinary tract infection (UTI), pulmonary and skin are recurrent foci. Thus, preventive measures, early diagnosis and proper management are crucial to reduce morbidity and mortality.

Objectives: Analyze the epidemiology of admitted cirrhoticsat tertiary hospital, their infection, prognosis and mortality.

Methods: Retrospective observational study by analyzing 134 hospitalizations (103 patients) from 06/01/2018 to 05/31/2019. Inclusion: diagnosed cirrhotics (clinic/image). Exclusion: elective hospitalization.

Results: 71 men and 32 women. Mediumage 58.4 ± 12.3. Etiologies: alcoholic 46 patients; NAFLD 22; hepatitis C 12. Of all, 45 admissions (33.58%) had community infections - prevalent UTI followed by SBP. Among this 45 hospitalizations, 12 (26.66%) reinfected during the stay. Overall death rate was 31%. Deaths: 2 without infection (71 hospitalizations); 30 infected (63 hospitalizations). In-hospital infections: 18 hospitalizations (13.4%), UTI principally, of which 11 patients died, 8 (72.72%) due to infection. Admission's Child-Pugh (CP) and Meld scores, by site: pulmonary (CP 11 ± 2.05; Meld 27 ± 10.02); 2 focus (CP 10.1 ± 1.86; Meld 23.8 ± 2.92); indeterminate (CP 10.1 ± 2.63; Meld 23.3 ± 8.31); urinary (CP 10.2 ± 2.64; Meld 21.5 ± 10.50); PBE (CP 9.8 ± 1.39; Meld 20.8 ± 4.21); intestinal (CP 9.8 ± 2.31; Meld 21.8 ± 7.68); cutaneous (CP 9.4 ± 0.89; Meld 18.2 ± 2.38); bloodstream (C 7.5 ± 0.70; Meld 16 ± 9.89). Death rate by site: indeterminate 83.3%; 2 sites 71.4%; pulmonary 60%; bloodstream 50%; UTI 35.3%; Intestinal 33.3%; SBP 30%; cutaneous 20%.

Conclusion: The most admitted cirrhotics are men and alcoholic etiology. Undetermined focus infections, 2 sites and lungs had higher mortality and CP/Meld scores on admission. Therefore, broad-spectrum empirical antibiotic therapy and semi-intensive care to this population are recommended.

https://doi.org/10.1016/j.aohep.2021.100418

P-55 QUALITY OF LIFE IMPROVES IN PATIENTS WITH OR WITHOUT CIRRHOSIS AFTER HEPATITIS C CURE WITH DIRECT-ACTING ANTIVIRAL AGENTS

Lucrecia Garcia Olveira[1], Sebastián Marciano[1,2],
Leila Haddad[1], Monica Fabiola Vasquez Palacios[3],
Diego Giunta[2], Adrian Gadano[1,2]

[1] *Hospital Italiano de Buenos Aires, Liver Unit, Ciudad de Buenos Aires, Argentina*
[2] *Hospital Italiano de Buenos Aires, Department of Research, Ciudad de Buenos Aires, Argentina*
[3] *Hospital Universitario del Rio, Cuenca, Ecuador*

Background: The effect of the treatment of chronic hepatitis C (CHC) with direct-acting antiviral agents (DAAs) on health- related quality of life (HRQL) has been mostly evaluated in clinical trials, and infrequently in Latin-American patients.

Aims: To evaluate the effect of CHC treatment with DAAs on HRQL in patients who achieved sustained virological response (SVR) in a real-life setting.

Materials and Methods: Prospective cohort study of consecutive adult patients with chronic hepatitis C who achieved SVR with DAAs from August/2017 to December/2018 at Hospital Italiano de Buenos Aires (Argentina). To evaluate HRQL, SF-12v2® Health Survey (SF-12v2) was administered before treatment, at its end, and 12-16 weeks after treatment ended (follow-up visit). QualityMetric-2009 General Population Sample was used as a reference to compare summary scores. The survey has two main summary domains: the physical component summary score (PCS) and the mental component summary score (MCS). Changes over time > 3 points are considered significant.

Results: A total of 159 patients were included, median age 59 (50-69) years-old, 103 (65%) had cirrhosis [85 (83%) Child A; 18 (17%) Child B]. Most patients (80%) received daclatasvir plus sofosbuvir, with or without ribavirin. Median treatment duration was 12 (12-24) weeks. At baseline, both PCS and MCS were below the mean reference of the standard population and showed a significant and progressive improvement over time. The overall mean change on PCS from basal visit to follow-up visit was 4.33 points (95% CI: 2.93-5.73 points). The overall mean change on MCS from pre-treatment visit to follow-up visit was 4.89 points (95% CI: 2.75-6.53 points). In the subgroup of patients with cirrhosis, a significant improvement in both PCS and MCS was also observed. (Figure).

Conclusion: HRQL significantly improved in Latin-American patients with CHC who achieved SVR with DAAs, even in those with cirrhosis.



https://doi.org/10.1016/j.aohep.2021.100419